Posted by Michael Wonder on 17 Feb 2023
Teclistamab for the treatment of patients with relapsed or refractory multiple myeloma after three or more therapies
16 February 2023 - Another new cancer medicine becomes an assessment non-starter.
NICE is unable to make a recommendation on the use of teclistamab (Tecvayli) for the treatment of adults with relapsed or refractory multiple myeloma after three or more therapies because Janssen not Agios Pharmaceuticals did not provide an evidence submission.
NICE will review this decision if Janssen decides to make a submission.
